Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMEVAAV

Financiado

Cerrado

Generation of Novel Cardiotropic AAV Based Serotypes to Evade Human Humoral Immu...

Generation of Novel Cardiotropic AAV Based Serotypes to Evade Human Humoral Immunity Cardiovascular diseases remain the primary cause of morbidity and mortality in the western countries. Pharmacological treatment improves survival and quality of life, but does not reverse disease progression. Gene therapy could fi... ver más

30/09/2016

UKHD

217K€

Presupuesto del proyecto: 217K€

Líder del proyecto

UNIVERSITATSKLINIKUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2016-09-30 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

UKHD

0.00€ | Lider

Proyectos interesantes

ARDAT

Medical Technol...

Biotechnology

25M€ Cerrado

CPP2021-008999

Medical Technol...

Genetics

774K€ Cerrado

TRACTION

Medical Technol...

Biotechnology

2M€ Cerrado

AAVolution

Medical Technol...

Biotechnology

5M€ Cerrado

AAVolution

Medical Technol...

Data Science

5M€ Cerrado

AD-VEC

Medical Technol...

Biotechnology

2M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

UNIVERSITATSKLINIKUM HEIDELBERG No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 217K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Cardiovascular diseases remain the primary cause of morbidity and mortality in the western countries. Pharmacological treatment improves survival and quality of life, but does not reverse disease progression. Gene therapy could fill this void, owing to its ability to treat the underlying cause. Adeno-associated viruses (AAV) emanated in the past decade as potent vectors, owing to their tropism for specific tissues, their low immunogenicity, their lack of pathogenicity and their ability to sustain long-term expression. As a testament to their potential, the European Commission approved the first gene therapy (Glybera) and several cardiac gene therapy clinical trials, one phase IIb, are underway using AAVs for gene targeting. Despite their growing success, a major impediment is the presence of pre-existing antibodies in patient serum, which excludes almost 50% of the population from clinical trials. The currently prominent approach, generation of novel serotypes from the known cardiotropic ones (AAV6 and 9) by random mutagenesis, alters favorable serotype attributes and most importantly tropism. Our goal is to generate novel serotypes based on AAV6 and 9, using a directed mutagenesis approach, against only the amino acids involved in neutralization but not receptor binding and therefore tropism. The mutant AAVs will be tested in vitro and in vivo for neutralization, transduction efficiency and cardiac tropism. Alternatively, a semi-random mutagenesis library approach focusing on 3-5 key amino acids will be pursued. Overall, the proposed study, using standard molecular biology techniques, will produce an immunogenic map of the cardiotropic AAVs, generate a panel of novel AAVs that evade humoral immunity but retain tropism, and therefore unequivocally provide with most needed vectors for human clinical trials and the opportunity for personalized medicine. Finally, this strategy will provide a proof of principle for other serotypes and diseases.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores